Global Natural Killer (NK) Cell Therapeutics Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Natural Killer (NK) Cell Therapeutics Market Research Report 2024
Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
According to Mr Accuracy reports’s new survey, global Natural Killer (NK) Cell Therapeutics market is projected to reach US$ 324.8 million in 2034, increasing from US$ 255.8 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Natural Killer (NK) Cell Therapeutics market research.
The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.
Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).
Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Natural Killer (NK) Cell Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Chipscreen Biosciences
Affimed NV
Altor BioScience
Innate Pharma
Takeda
Sorrento Therapeutics
NantKwest
Bristol-Myers Squibb
NKT
Henry Ford Health Services
Segment by Type
Mogamulizumab
Lorvotuzumab Mertansine
Others
Cancer
Cardiovascular Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Natural Killer (NK) Cell Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Natural Killer (NK) Cell Therapeutics market is projected to reach US$ 324.8 million in 2034, increasing from US$ 255.8 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Natural Killer (NK) Cell Therapeutics market research.
The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.
Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).
Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Natural Killer (NK) Cell Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chipscreen Biosciences
Affimed NV
Altor BioScience
Innate Pharma
Takeda
Sorrento Therapeutics
NantKwest
Bristol-Myers Squibb
NKT
Henry Ford Health Services
Segment by Type
Mogamulizumab
Lorvotuzumab Mertansine
Others
Segment by Application
Cancer
Cardiovascular Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Natural Killer (NK) Cell Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices